The possible cost effectiveness of peripheral blood stem cell mobilization with clophosphamide and the late addition of G-CSF
Journal of Korean Medical Science
;
: 49-52, 2000.
Artículo
en Inglés
| WPRIM
| ID: wpr-43385
ABSTRACT
The purpose of this study was to develop a cost-effective protocol for the mobilization of peripheral blood stem cells (PBSC) in patients with malignancy. Thirty consecutive patients were randomized to mobilize PBSC with the late addition of a standard 250 microg dose of G-CSF (Neutrogen) from day 8 or early addition of the same dose of G-CSF from day 2, following cyclophosphamide (CY) 4 g/m2. The median yield of CD34+ cells from evaluated patients was 7.87 x 10(6)/kg (range, 2.06-27.25), collected in a median of four apheresis (range, 2-9). Target CD34 + cell doses > or = 2.0 x 10(6)/kg were achieved in all patients able to be evaluated. There were no statistically significant differences in CD34+ cell yields or toxicities. Overall engraftment occurred with median days to neutrophils > or = 0.5 x 10(9)/L or platelets > 20 x 10(9)/L of 11 and 17 days, respectively. However, the duration of G-CSF administration was markedly shorter in the late use of G-CSF group than in the early use of G-CSF group, with a median of 9 days compared with 15 days (p>0.001). PBSC harvesting after priming with CY plus delayed use of G-CSF made it a safe and cost-effective procedure.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Sarcoma de Ewing
/
Linfoma no Hodgkin
/
Neoplasias de la Mama
/
Esquema de Medicación
/
Células Madre Hematopoyéticas
/
Estudio Comparativo
/
Factor Estimulante de Colonias de Granulocitos
/
Análisis Costo-Beneficio
/
Trasplante de Células Madre Hematopoyéticas
/
Antineoplásicos Alquilantes
Tipo de estudio:
Ensayo Clínico Controlado
/
Evaluación Económica en Salud
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Journal of Korean Medical Science
Año:
2000
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS